Evidence map›Paper›PMID 25771402›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

Kristin Baird, Leora E Comis, Galen O Joe, Seth M Steinberg, Fran T Hakim, Jeremy J Rose, Sandra A Mitchell, Steven Z Pavletic, William D Figg, Lawrence Yao and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00702689 (A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00702689 phase2completednot on this map

A Phase II Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2008 to 2020Enrolled20ConditionsSclerotic Graft Versus Host Disease, Imatinib MesylateArmsGleevec, STI571(Imatinib Mesylate)
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  4. Trial
  5. Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  6. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Kristin BairdPediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Leora E ComisRehabilitation Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Galen O JoeRehabilitation Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Seth M SteinbergBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Fran T HakimExperimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Jeremy J RoseExperimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Sandra A MitchellOutcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland.
Steven Z PavleticExperimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
William D FiggMedical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Lawrence YaoRadiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Kathleen C FlandersLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Naoko TakebeCancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stefanie SarantopoulosDivision of Hematologic Malignancy and Cell Therapy and Duke Cancer Institute, Department of Medicine, Duke University, Durham, North Carolina.
Susan BooherAutoimmunity and Mucosal Immunology Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
Edward W CowenDermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: edcowen@hotmail.com.
National Institutes of Health · USNational Cancer Institute · USNational Institutes of Health Clinical Center · USDuke University · USNational Institute of Allergy and Infectious Diseases · US

Funding

Chronic graft-versus-host diseaseZIABC011549 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI COWEN, EDWARD · 2014 to 2021
$5.2M
Intramural NIH HHS ZIA BC011549
6 · The paper itself

Abstract

Sclerotic skin manifestations of chronic graft-versus-host disease (ScGVHD) lead to significant morbidity, including functional disability from joint range of motion (ROM) restriction. No superior second-line therapy has been established for steroid-refractory disease. Imatinib mesylate is a multikinase inhibitor of several signaling pathways implicated in skin fibrosis with in vitro antifibrotic activity. We performed an open-label pilot phase II trial of imatinib in children and adults with corticosteroid-refractory ScGVHD. Twenty patients were enrolled in a 6-month trial. Eight received a standard dose (adult, 400 mg daily; children, 260 mg/m(2) daily). Because of poor tolerability, 12 additional patients underwent a dose escalation regimen (adult, 100 mg daily initial dose up to 200 mg daily maximum; children, initial dose 65 mg/m(2) daily up to 130 mg/m(2) daily). Fourteen patients were assessable for primary response, improvement in joint ROM deficit, at 6 months. Primary outcome criteria for partial response was met in 5 of 14 (36%), stable disease in 7 of 14 (50%), and progressive disease in 2 of 14 (14%) patients. Eleven patients (79%), including 5 with partial response and 6 with stable disease, demonstrated a positive gain in ROM (range of 3% to 94% improvement in deficit). Of 13 patients with measurable changes at 6 months, the average improvement in ROM deficit was 24.2% (interquartile range, 15.5% to 30.5%; P = .011). This trial is registered at http://clinicaltrials.gov as NCT007020689.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAntineoplastic AgentsChildDrug Administration ScheduleFasciitisFemaleGraft vs Host DiseaseHumansImatinib MesylateJointsLeukemiaMaleMiddle AgedMycophenolic AcidAntineoplastic AgentsImatinib MesylateMycophenolic AcidPrednisoneTacrolimusAllogeneic hematopoietic stem cell transplantationFasciitisGraft-versus-host diseaseImatinib mesylateSclerosis

Identifiers

PMID25771402
PMCPMC4425991
OpenAlexW1982383053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.